Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Post by Royal10on Mar 08, 2018 2:12pm
164 Views
Post# 27685183

ARZ: expect strong results for year 2017, next week!

ARZ: expect strong results for year 2017, next week!
Please, read: "Our performance in the third quarter demonstrates the strength of our underlying business, with growth in the U.S. and Canada, and puts us on the path to profitability as reflected by the achievement of positive quarterly adjusted earnings before interest, taxes, depreciation and amortization for the first time as Aralez," said Adrian Adams, chief executive officer of Aralez. "We are delighted with the evolution of Zontivity , the improved outlook for the Toprol-XL franchise in the U.S. and the continued strong performance of the Canadian business. As a result of this performance, we updated our 2017 financial guidance and now expect full-year net revenue to be in the range of $95-million to $105-million."
<< Previous
Bullboard Posts
Next >>